TEL AVIV, Israel – A presentation in early June to the American Society of Clinical Oncology (ASCO) will mark yet another small step in Israeli firm Compugen Ltd.'s ongoing effort to transform itself from a computational drug target discovery company into a preclinical or even clinical-stage drug company.